Literature DB >> 33628601

Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas.

Xianchun Gao1, Yanan Pan2, Weili Han1, Caie Hu3, Chenchen Wang1, Ling Chen4, Yong Guo4, Yupeng Shi1, Yan Pan1, Huahong Xie1, Liping Yao1, Jianjun Yang1, Jianyong Zheng1, Xiaohua Li1, Xiaonan Liu1, Liu Hong1, Jipeng Li1, Mengbin Li1, Gang Ji1, Zengshan Li4, Jielai Xia5, Qingchuan Zhao1, Daiming Fan1, Kaichun Wu1, Yongzhan Nie1.   

Abstract

Objective: The systemic inflammation index and body mass index (BMI) are easily accessible markers that can predict mortality. However, the prognostic value of the combined use of these two markers remains unclear. The goal of this study was therefore to evaluate the association of these markers with outcomes based on a large cohort of patients with gastric cancer.
Methods: A total of 2,542 consecutive patients undergoing radical surgery for gastric or gastroesophageal junction adenocarcinoma between 2009 and 2014 were included. Systemic inflammation was quantified by the preoperative neutrophil-to-lymphocyte ratio (NLR). High systemic inflammation was defined as NLR ≥ 3, and underweight was defined as BMI < 18.5 kg/m2.
Results: Among 2,542 patients, NLR ≥ 3 and underweight were common [627 (25%) and 349 (14%), respectively]. In the entire cohort, NLR ≥ 3 or underweight independently predicted overall survival (OS) [hazard ratio (HR): 1.236, 95% confidence interval (95% CI): 1.069-1.430; and HR: 1.600, 95% CI: 1.350-1.897, respectively] and recurrence-free survival (RFS) (HR: 1.230, 95% CI: 1.054-1.434; and HR: 1.658, 95% CI: 1.389-1.979, respectively). Patients with both NLR ≥ 3 and underweight (vs. neither) had much worse OS (HR: 2.445, 95% CI: 1.853-3.225) and RFS (HR: 2.405, 95% CI: 1.802-3.209). Furthermore, we observed similar results in subgroup analyses according to pathological stage, age, and postoperative chemotherapy. Conclusions: Our results showed that preoperative elevated NLR and decreased BMI had a significant negative effect on survival. Underweight combined with severe inflammation could enhance prognostication. Taking active therapeutic measures to reduce inflammation and increase nutrition may help improve outcomes. Copyright:
© 2021, Cancer Biology & Medicine.

Entities:  

Keywords:  Gastric cancer; body mass index; neutrophil-to-lymphocyte ratio; prognosis; systemic inflammation index

Mesh:

Substances:

Year:  2021        PMID: 33628601      PMCID: PMC7877168          DOI: 10.20892/j.issn.2095-3941.2020.0246

Source DB:  PubMed          Journal:  Cancer Biol Med        ISSN: 2095-3941            Impact factor:   4.248


  47 in total

1.  Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer.

Authors:  X Xie; K-J Luo; Y Hu; J-Y Wang; J Chen
Journal:  Dis Esophagus       Date:  2014-11-19       Impact factor: 3.429

2.  Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.

Authors:  T Grenader; S Nash; Y Plotkin; J Furuse; N Mizuno; T Okusaka; H Wasan; J Valle; J Bridgewater
Journal:  Ann Oncol       Date:  2015-06-02       Impact factor: 32.976

3.  The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients.

Authors:  Ryoichi Miyamoto; Satoshi Inagawa; Naoki Sano; Sosuke Tadano; Shinya Adachi; Masayoshi Yamamoto
Journal:  Eur J Surg Oncol       Date:  2018-02-13       Impact factor: 4.424

4.  Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.

Authors:  Alessandro Parisi; Alessio Cortellini; Michela Roberto; Olga Venditti; Daniele Santini; Emanuela Dell'Aquila; Marco Stellato; Paolo Marchetti; Mario Alberto Occhipinti; Federica Zoratto; Federica Mazzuca; Nicola Tinari; Michele De Tursi; Laura Iezzi; Clara Natoli; Margherita Ratti; Claudio Pizzo; Michele Ghidini; Giampiero Porzio; Corrado Ficorella; Katia Cannita
Journal:  J Cancer Res Clin Oncol       Date:  2019-07-06       Impact factor: 4.553

5.  Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.

Authors:  T Grenader; T Waddell; C Peckitt; J Oates; N Starling; D Cunningham; J Bridgewater
Journal:  Ann Oncol       Date:  2016-01-19       Impact factor: 32.976

6.  Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.

Authors:  Jordi Bruix; Ann-Lii Cheng; Gerold Meinhardt; Keiko Nakajima; Yoriko De Sanctis; Josep Llovet
Journal:  J Hepatol       Date:  2017-07-04       Impact factor: 25.083

7.  Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue.

Authors:  Yu Si; Simon F Merz; Philipp Jansen; Baoxiao Wang; Kirsten Bruderek; Petra Altenhoff; Stefan Mattheis; Stephan Lang; Matthias Gunzer; Joachim Klode; Anthony Squire; Sven Brandau
Journal:  Sci Immunol       Date:  2019-10-18

8.  Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients.

Authors:  Jun Lu; Long-Long Cao; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Qi-Yue Chen; Mi Lin; Ru-Hong Tu; Chang-Ming Huang; Chao-Hui Zheng
Journal:  Gastroenterol Res Pract       Date:  2018-07-11       Impact factor: 2.260

9.  Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis.

Authors:  Hao Peng; Xiaogang Luo
Journal:  Cancer Cell Int       Date:  2019-03-25       Impact factor: 5.722

10.  An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma.

Authors:  A Ari Hakimi; Helena Furberg; Emily C Zabor; Anders Jacobsen; Nikolaus Schultz; Giovanni Ciriello; Nina Mikklineni; Brandon Fiegoli; Philip H Kim; Martin H Voss; Hui Shen; Peter W Laird; Chris Sander; Victor E Reuter; Robert J Motzer; James J Hsieh; Paul Russo
Journal:  J Natl Cancer Inst       Date:  2013-11-27       Impact factor: 13.506

View more
  1 in total

1.  Cell pyroptosis in health and inflammatory diseases.

Authors:  Yongqi Wu; Jing Zhang; Sihui Yu; Yan Li; Jinrong Zhu; Kai Zhang; Rongxin Zhang
Journal:  Cell Death Discov       Date:  2022-04-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.